The objective of this core is to provide a resource for preclinical evaluation of new compounds synthesized at The University of Michigan and Wayne State University for antiviral activity against members of the herpesvirus group. Initially, the antiviral activity against Herpes Simplex virus types 1 and 2 (HSV-1, HSV-2) and cytomegalovirus (CMV) will be confirmed and also tested against murine CMV (MCMV), Varicella-Zoster virus (VZV), Epstein-Barr virus (EBV), Human Herpesvirus Type 6 (HHV-6), and Human Herpesvirus Type 8 (HHV-8). Efficacy, cell cytotoxicity, and anti- proliferative activity will be assessed in cultures of human and mouse cells. Compounds that have good in vitro activity and low toxicity against HSV-l, HSV-2, or MCMV will then be tested in experimental animal infections which are established models of severe human herpesvirus infections. The animal models to be utilized include: l) intraperitoneal inoculation of normal mice with MCMV, a model for acute and chronic disseminated disease; 2) intraperitoneal inoculation of severe combined immunodeficient (SCID) mice with MCMV, a model for acute disseminated CMV disease in the immunocompromised host; 3) SClD mice implanted with human fetal tissue which will then be infected with HCMV; 4) intraperitoneal inoculation of weanling mice with HSV-l, a model for herpes encephalitis; and 5) intraperitoneal inoculation of weanling mice with HSV-2, a model for neonatal herpes. The animal model systems have been developed to: 1) simulate a human herpesvirus disease; 2) utilize a natural route of infection where possible; 3) achieve infection or mortality rates of 80-90% so that a maximum level of sensitivity in determining antiviral activity can be obtained; 4) evaluate several concentrations of drug initiated at various times after viral challenge; and 5) determine the effect of antiviral therapy on mortality, mean day of death, and viral replication in major target organs. For promising lead compounds, pharmacokinetics, oral bioavailability, and toxicity to the major organ systems will be performed in mice.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI046390-02
Application #
6344681
Study Section
Special Emphasis Panel (ZAI1)
Project Start
2000-09-30
Project End
2001-09-29
Budget Start
Budget End
Support Year
2
Fiscal Year
2000
Total Cost
$187,307
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Chien, Tun-Cheng; Drach, John C; Townsend, Leroy B (2008) Design and synthesis of 1-(beta-D-ribofuranosyl)imidazo[4,5-c]pyrazoles as 5:5 bicyclic analogs of purine nucleosides. Nucleic Acids Symp Ser (Oxf) :593-4
Zhou, Shaoman; Zemlicka, Jiri; Kern, Earl R et al. (2007) Fluoroanalogues of anti-cytomegalovirus agent cyclopropavir: synthesis and antiviral activity of (E)- and (Z)-9-{[2,2-bis(hydroxymethyl)-3-fluorocyclopropylidene]methyl}-adenines and guanines. Nucleosides Nucleotides Nucleic Acids 26:231-43
Qin, Xinrong; Chen, Xinchao; Wang, Kun et al. (2006) Synthesis, antiviral, and antitumor activity of 2-substituted purine methylenecyclopropane analogues of nucleosides. Bioorg Med Chem 14:1247-54
Zhou, Shaoman; Kern, Earl R; Gullen, Elizabeth et al. (2006) 9-{[3-fluoro-2-(hydroxymethyl)cyclopropylidene]methyl}adenines and -guanines. Synthesis and antiviral activity of all stereoisomers1. J Med Chem 49:6120-8
Lorenzi, Philip L; Landowski, Christopher P; Brancale, Andrea et al. (2006) N-methylpurine DNA glycosylase and 8-oxoguanine dna glycosylase metabolize the antiviral nucleoside 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole. Drug Metab Dispos 34:1070-7
Ambrose, Amalraj; Zemlicka, Jiri; Kern, Earl R et al. (2005) Phosphoralaninate pronucleotides of pyrimidine methylenecyclopropane analogues of nucleosides: synthesis and antiviral activity. Nucleosides Nucleotides Nucleic Acids 24:1763-74
Yan, Zhaohua; Kern, Earl R; Gullen, Elizabeth et al. (2005) Nucleotides and pronucleotides of 2,2-bis(hydroxymethyl)methylenecyclopropane analogues of purine nucleosides: synthesis and antiviral activity. J Med Chem 48:91-9
Kern, Earl R; Kushner, Nicole L; Hartline, Caroll B et al. (2005) In vitro activity and mechanism of action of methylenecyclopropane analogs of nucleosides against herpesvirus replication. Antimicrob Agents Chemother 49:1039-45
Chien, Tun-Cheng; Berry, David A; Drach, John C et al. (2005) Synthesis of 3-aminoimidazo[4,5-c]pyrazole nucleoside via the N-N bond formation strategy as a [5:5] fused analog of adenosine. Nucleosides Nucleotides Nucleic Acids 24:1971-96
Lorenzi, Philip L; Landowski, Christopher P; Song, Xueqin et al. (2005) Amino acid ester prodrugs of 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole enhance metabolic stability in vitro and in vivo. J Pharmacol Exp Ther 314:883-90

Showing the most recent 10 out of 41 publications